Compounders Research Compare

Prime Medicine, Inc.(PRME)

Biotechnology · Cambridge, MA

$3.49+0.27 (+8.57%)

Delayed quote: Oct 6, 2026, 1:55 PM EDT

About Prime Medicine, Inc.

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.

Cambridge, MA

146 employees

www.primemedicine.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Allan Reine

View full financials

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T17:57:52.954Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:57:52.954Z.

Quote observation: 2026-10-06T17:55:13.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 629,451,813
TTM free cash flow · period ending 2026-06-30: -156,848,000

FMP input reference: ed0d84ebe65fc765338e7baf7154c4548c52c7814b601df66b93f049f622236d

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

PRME Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

PRME Competitors' Price/FCF Ratio

Prime Medicine, Inc.

Current

Market Cap

$629.45M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SOPHiA GENETICS S.A.

Market Cap

$634.15M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aura Biosciences, Inc.

Market Cap

$634.07M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OmniAb, Inc.

Market Cap

$639.31M

Price/FCF Ratio

N/A

TTM Avg

697.87

3Y Avg

748.88

5Y Avg

748.88

Climb Bio, Inc.

Market Cap

$615.86M

Price/FCF Ratio

N/A

TTM Avg

3847.94

3Y Avg

3847.94

5Y Avg

3847.94

Starling Oncology, Inc.

Market Cap

$657.51M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Ironwood Pharmaceuticals, Inc.

Market Cap

$600.59M

Price/FCF Ratio

3.24

TTM Avg

7.03

3Y Avg

5.99

5Y Avg

6.65

AngioDynamics, Inc.

Market Cap

$596.40M

Price/FCF Ratio

1174.01

TTM Avg

742.47

3Y Avg

742.47

5Y Avg

415.90

Annexon, Inc.

Market Cap

$664.38M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

4D Molecular Therapeutics, Inc.

Market Cap

$667.05M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Prime Medicine, Inc. (PRME)	$629.45M	N/A	N/A	N/A	N/A
SOPHiA GENETICS S.A. (SOPH)vs ›	$634.15M	N/A	N/A	N/A	N/A
Aura Biosciences, Inc. (AURA)vs ›	$634.07M	N/A	N/A	N/A	N/A
OmniAb, Inc. (OABI)vs ›	$639.31M	N/A	697.87	748.88	748.88
Climb Bio, Inc. (CLYM)vs ›	$615.86M	N/A	3847.94	3847.94	3847.94
Starling Oncology, Inc. (STLN)vs ›	$657.51M	N/A	N/A	N/A	N/A
Ironwood Pharmaceuticals, Inc. (IRWD)vs ›	$600.59M	3.24	7.03	5.99	6.65
AngioDynamics, Inc. (ANGO)vs ›	$596.40M	1174.01	742.47	742.47	415.90
Annexon, Inc. (ANNX)vs ›	$664.38M	N/A	N/A	N/A	N/A
4D Molecular Therapeutics, Inc. (FDMT)vs ›	$667.05M	N/A	N/A	N/A	N/A

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Growth Operating Margin All Metrics